Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients
Authors: Andre C. Kalil, Julie Stoner
Journal: Annals of Internal Medicine (2006)

Letters21 March 2006Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant RecipientsAndre C. Kalil, MD and Julie Stoner, PhDAndre C. Kalil, MDFrom the University of Nebraska, Nebraska Medical Center, Omaha, NE 68198-5400.Search for more papers by this author and Julie Stoner, PhDFrom the University of Nebraska, Nebraska Medical Center, Omaha, NE 68198-5400.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-144-6-200603210-00025 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We appreciate Dr. Singh's and Ms. Wagener's comments but must address several points of disagreement. First, we do not agree that our conclusions may be misleading. As discussed in our paper, trial design limitations, duration of follow-up, and prophylaxis were thoroughly evaluated by sensitivity analyses, and the conclusions of our meta-analysis remained unchanged.Second, Dr. Singh and Ms. Wagener do not feel that the studies by Hibberd (1) and Conti (2) and colleagues can truly be considered preemptive therapy. Of interest, both of these studies have the words “preemptive ganciclovir therapy” in their titles. After considering the objectives ...References1. Hibberd PL, Tolkoff-Rubin NE, Conti D, Stuart F, Thistlethwaite JR, Neylan JF, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized, controlled trial. Ann Intern Med. 1995;123:18-26. [PMID: 7762909] LinkGoogle Scholar2. Conti DJ, Freed BM, Singh TP, Gallichio M, Gruber SA, Lempert N. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients. Arch Surg. 1995;130:1217-21. [PMID: 7487465] CrossrefMedlineGoogle Scholar3. Rayes N, Seehofer D, Schmidt CA, Oettle H, Muller AR, Steinmuller T, et al. Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation. Transplantation. 2001;72:881-5. [PMID: 11571454] CrossrefMedlineGoogle Scholar4. Sagedal S, Nordal KP, Hartmann A, Midtvedt K, Foss A, Asberg A, et al. Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study. Nephrol Dial Transplant. 2003;18:1899-908. [PMID: 12937241] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Andre C. Kalil, MD; Julie Stoner, PhDAffiliations: From the University of Nebraska, Nebraska Medical Center, Omaha, NE 68198-5400.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPreemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Cytomegalovirus Antibody-Positive Renal Transplant Recipients Patricia L. Hibberd , Nina E. Tolkoff-Rubin , David Conti , Frank Stuart , J. Richard Thistlethwaite , John F. Neylan , David R. Snydman , Richard Freeman , Marc I. Lorber , and Robert H. Rubin Meta-Analysis: The Efficacy of Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients Andre C. Kalil , Josh Levitsky , Elizabeth Lyden , Julie Stoner , and Alison G. Freifeld Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients Nina Singh and Marilyn M. Wagener Metrics 21 March 2006Volume 144, Issue 6Page: 457KeywordsBacterial diseasesConflicts of interestCytomegalovirus infectionFungal diseasesImmunohistochemistryOpportunistic infectionsProphylaxis ePublished: 21 March 2006 Issue Published: 21 March 2006 Copyright & PermissionsCopyright © 2006 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...